Editor's note: The study referenced below shows clinical effectiveness for treating anaplasmosis with enrofloxacin. Only Baytril 100-CA1 is approved for treatment of clinical anaplasmosis.
In this roundup of bovine medical news, we share information about a new study showing promise for treatment of clinical anaplasmosis. And there's a new product that tackles pneumonia in cattle.
Taking on anaplasmosis
Anaplasmosis is a vector-borne, infectious blood disease usually spread by ticks. The feeding tick transmits the bacteria that infects red blood cells and cause severe anemia. The disease is most devastating to cows ages 3 and older.
A new study demonstrated that enrofloxacin administered subcutaneously at a dose of 5.7 mL/100 lbs of body weight (5.7 mg/lb; 12.5 mg/kg of BW) improved treatment success and mortality outcomes when administered to cows with clinical anaplasmosis. Mortality was reduced from 47% to 3% (p = 0.0027). The research was published recently in The Bovine Practitioner, the journal of the American Association of Bovine Practitioners.
“This work allowed us to study anaplasmosis and therapeutic intervention with enrofloxacin in mature cattle in a scale not previously reported in the literature," says Douglas Shane, DVM, pH D, project architect – Farm Animal, Next Generation Development with Elanco Animal Health and lead author of the study. "Understanding the disease and therapeutic intervention in mature cattle is of utmost importance because cattle greater than 2 years of age are the most likely to suffer from clinical anaplasmosis and die as a result. Results of this study indicate that enrofloxacin improves treatment success and mortality outcomes in cattle with anaplasmosis compared to saline controls.”
Shane adds: “Anemia and weakness are frequently the first clinical signs. Infected cattle will fall behind the rest of the herd and will not eat or drink. Weight loss is rapid. It is not unusual for the first indication a producer has of anaplasmosis in a herd is upon finding a dead cow."
Shane advises producers to consult with their veterinarians to help develop a plan for dealing with anaplasmosis, as well as developing an effective tick control program. "Veterinarians and producers should remain aware that extra-label use of fluoroquinolones in food animals is illegal in the United States. Elanco is pleased to offer Baytril 100-CA1, a conditionally approved enrofloxacin product for treatment of clinical anaplasmosis."
Learn more at elancolivestock.com.
New pneumonia preventive
Merck Animal Health has announced that Bovilis Nasalgen 3-PMH is now available to veterinarians and cattle producers to protect cattle from five of the most common pneumonia-causing viral and bacterial pathogens. Approved for use in dairy and beef cattle, this is the first intranasal vaccine effective in providing early, broad-spectrum respiratory protection against both viral and bacterial pathogens in a needle free, animal- and BQA-friendly administration. It is the first intranasal BRD vaccine against viral and bacterial pneumonia.
“Bovilis Nasalgen 3-PMH is a modified-live, intranasal vaccine that stimulates a strong early immune response to help give calves a strong foundation of respiratory disease protection,” says Scott Nordstrom, D.V.M., director of livestock innovation and discovery, Merck Animal Health. “Results of efficacy, duration of immunity and safety studies demonstrate the vaccine is safe and effective for calves at 1 week of age or older.”
The vaccine protects against infectious bovine rhinotracheitis (IBR), bovine respiratory syncytial virus (BRSV), parainfluenza 3 (PI3), Mannheimia haemolytica and Pasteurella multocida.
Veterinarians and producers can now purchase Bovilis Nasalgen 3-PMH. The vaccine is administered in a single 2-mL dose. It contains a unique BluShadow diluent that clearly indicates which animals have been vaccinated. With needle-free intranasal administration, the vaccine meets best management practices outlined in the industry’s Beef Quality Assurance program.
Learn more at merck-animal-health-usa.com
Source: Baytril 100-CA1, Elanco. Bovilis Nasalgen 3- PMH, Merck. The source is solely responsible for the information provided and is wholly owned by the source. Informa Business Media and all its subsidiaries are not responsible for any of the content contained in this information asset.